Millennium Management’s Amicus Therapeutics FOLD Stock Holding History

Millennium Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$712K	–	5927
2025 Q4	$712K	Sell	50,000 -122,500	-71%	-$1.2M	﹤0.01%	4712
2025 Q3	$1.36M	Buy	+172,500	New	+$1.23M	﹤0.01%	4376
2021 Q1	–	Sell	-60,000	Closed	-$1.39M	–	6104
2020 Q4	$1.39M	Buy	+60,000	New	+$1.23M	﹤0.01%	3507
2015 Q2	–	Sell	-300,000	Closed	-$3.26M	–	3490
2015 Q1	$3.26M	Buy	+300,000	New	+$2.64M	0.01%	1656
2013 Q4	–	Sell	-200,000	Closed	-$464K	–	3543
2013 Q3	$464K	Sell	200,000 -200,000	-50%	-$502K	﹤0.01%	2599
2013 Q2	$932K	Buy	+400,000	New	+$1.23M	﹤0.01%	2001

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management's FOLD Position: Q1 2026 in Review

Millennium Management increased its Amicus Therapeutics (FOLD) stake by 164% in Q1 2026, buying an estimated $70.4M and bringing the position to 7,908,459 shares worth $114M. The position accounts for 0.05% of the portfolio, ranked #388.

Millennium Management first reported a position in FOLD in Q2 2014 and has held it in 39 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Millennium Management held 7,908,459 shares of Amicus Therapeutics worth $114M as of Q1 2026.
Millennium Management bought 4,913,370 Amicus Therapeutics shares in Q1 2026, an estimated $70.4M.
Amicus Therapeutics made up 0.05% of Millennium Management's portfolio in Q1 2026, its #388 holding.
Millennium Management first reported a position in Amicus Therapeutics in Q2 2014 and has held it in 39 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.